Abstract
Renin-angiotensin system (RAS) blockade has been associated with improved outcomes in numerous disease states, including reduced mortality in congestive heart failure (CHF), hypertension, and diabetes ([1][1],[2][2]). RAS blockade remains central to the management of both cardiovascular disease and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical journal of the American Society of Nephrology : CJASN
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
